Skip to Content

Triamcinolone nasal Pregnancy and Breastfeeding Warnings

Triamcinolone nasal is also known as: Allernaze, Nasacort, Nasacort AQ, Nasacort Allergy 24HR, Nasacort HFA

Medically reviewed by Last updated on Oct 21, 2019.

Triamcinolone nasal Pregnancy Warnings

Triamcinolone has been assigned to pregnancy category C by the FDA. At high doses, triamcinolone has been shown to be teratogenic in rabbits, rats, and monkeys. There are no controlled data in human pregnancy. Triamcinolone is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk.

See references

Triamcinolone nasal Breastfeeding Warnings

There are no data on the excretion of triamcinolone into human milk. However, other glucocorticoids are excreted into human milk in low concentrations. The manufacturer recommends that caution be used when administering triamcinolone to nursing women.

See references

References for pregnancy information

  1. "Product Information. Nasacort Allergy 24 HR (triamcinolone nasal)." Sanofi-Aventis, Laval, QC.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. TGA. Therapeutic Goods Administration. Australian Drug Evaluation Committee "Prescribing medicines in pregnancy: an Australian categorisation of risk of drug use in pregnancy. Available from: URL:" ([1999]):

References for breastfeeding information

  1. National Library of Medicine (US) "Drugs and Lactation Database (LactMed) Available from: URL:" (2006):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.